Bloat, pain and diarrhea rooted in the gastrointestinal (GI) tract can signal anything from mild indigestion to a devastating viral invasion. However, for millions of people around the globe, these are symptoms of an inflammatory bowel disease. Beginning at the lips, the GI tract breaks food down to access nutrients and eliminate waste. It’s easy to understand that anything interfering with the tract’s purpose, digestion, will also derail a balanced diet. Without treatment, adults can experience hair and weight loss, abscesses and anemia.
Bowel Disorders Strike Millions
According to the Crohn’s & Colitis Foundation of America, approximately 1.4 million Americans suffer from irritable bowel disease (IBD). Treatments ease symptoms and quell inflammation, but there is no cure for Crohn’s disease. Adults burdened with Crohn’s disease face financial hardship from their reduced ability to work coupled with treatment costs. However, children with IBD can also face childhood malnutrition and lifelong developmental impairments. But if science has its way, a new medication will make life easier for thousands of children suffering from Crohn’s disease, and their parents.
A pharmaceutical company is sending a new medication, Thetanix, through clinical trials. To get this drug to market as quickly as possible, they’ve hired a pharmaceutical consulting firm to manage all aspects of testing and data collection. Consulting firms understand regulations governing pharmaceutical testing.
New Medicines mean New Possibilities
Thetanix is more than a new medication to treat pediatric Crohn’s disease (PCD). It’s a member of a new class of drugs called live biotherapeutics. These pharmaceutical therapies use bacteria to treat or cure conditions, and since intestinal bacteria play a vital role in digestion, may be less disruptive to the GI tract’s native bacterial population. Research companies like http://www.gandlscientific.com/ recruit patient volunteers who serve as test subjects, train and place research teams and manage the resulting data.
Of the 41,000 US children suffering from PCD, almost 30 percent will face surgery within three years after diagnosis. Many will risk developing cancer from long-term steroid treatments meant to suppress inflammation and other troubling symptoms. With a gentler medication, parents can stop worrying that today’s treatment will be tomorrow’s disaster, or that their child’s growth will stop prematurely. The human trials that scientific research firms organize and staff may release patients and their parents from PCD’s burden.